Vor Biopharma Inc. VOR
We take great care to ensure that the data presented and summarized in this overview for Vor Biopharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VOR
View all-
Ra Capital Management, L.P. Boston, MA39.6MShares$65.8 Million1.4% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA6.36MShares$10.6 Million6.91% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.92MShares$3.18 Million0.0% of portfolio
-
Ubs Group Ag1.53MShares$2.54 Million0.0% of portfolio
-
Johnson & Johnson New Brunswick, NJ1.07MShares$1.78 Million0.59% of portfolio
-
Jane Street Group, LLC New York, NY526KShares$872,5170.0% of portfolio
-
Sarissa Capital Management LP Greenwich, CT508KShares$843,3060.61% of portfolio
-
Black Rock Inc. New York, NY498KShares$826,1750.0% of portfolio
-
Hrt Financial LP New York, NY475KShares$787,7940.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny468KShares$777,0650.0% of portfolio
Latest Institutional Activity in VOR
Top Purchases
Top Sells
About VOR
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at VOR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 17
2025
|
Qing Che Zuraw Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
937,080
+50.0%
|
-
|
|
Jul 09
2025
|
Sandesh Mahatme CFO |
BUY
Grant, award, or other acquisition
|
Direct |
13,882,750
+50.0%
|
-
|
|
May 06
2025
|
Tirtha Chakraborty Chief Sci Off & Head Tech Ops |
SELL
Payment of exercise price or tax liability
|
Direct |
876
-0.4%
|
$0
$0.56 P/Share
|
|
May 06
2025
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,361
-0.26%
|
$0
$0.56 P/Share
|
|
May 01
2025
|
Han Wook Choi Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,061
-3.86%
|
$0
$0.66 P/Share
|
|
May 01
2025
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,273
-0.29%
|
$0
$0.66 P/Share
|
|
May 01
2025
|
Tirtha Chakraborty Chief Sci Off & Head Tech Ops |
SELL
Payment of exercise price or tax liability
|
Direct |
1,947
-0.44%
|
$0
$0.66 P/Share
|
|
Feb 13
2025
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,227
-1.73%
|
$2,227
$1.42 P/Share
|
|
Feb 10
2025
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,554
-1.94%
|
$2,554
$1.37 P/Share
|
|
Feb 06
2025
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,180
-0.89%
|
$1,180
$1.5 P/Share
|
|
Feb 06
2025
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,787
-0.3%
|
$2,787
$1.5 P/Share
|
|
Feb 06
2025
|
Tirtha Chakraborty Chief Sci Off & Head Tech Ops |
SELL
Payment of exercise price or tax liability
|
Direct |
1,033
-0.47%
|
$1,033
$1.5 P/Share
|
|
Feb 03
2025
|
Han Wook Choi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+50.0%
|
-
|
|
Feb 03
2025
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+28.37%
|
-
|
|
Feb 03
2025
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,353
-1.66%
|
$1,353
$1.34 P/Share
|
|
Feb 03
2025
|
Tirtha Chakraborty Chief Sci Off & Head Tech Ops |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+19.18%
|
-
|
|
Feb 03
2025
|
Tirtha Chakraborty Chief Sci Off & Head Tech Ops |
SELL
Payment of exercise price or tax liability
|
Direct |
1,163
-0.68%
|
$1,163
$1.34 P/Share
|
|
Feb 03
2025
|
Robert Ang PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
137,500
+12.98%
|
-
|
|
Feb 03
2025
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,248
-0.41%
|
$3,248
$1.34 P/Share
|
|
Dec 30
2024
|
Reprogrammed Interchange LLC |
BUY
Open market or private purchase
|
Direct |
38,974,101
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 32M shares |
|---|---|
| Open market or private purchase | 39M shares |
| Payment of exercise price or tax liability | 55.6K shares |
|---|---|
| Open market or private sale | 15.1K shares |